Guggenheim Rates Amylyx Pharmaceuticals (AMLX) buy
Guggenheim maintains its buy rating on AMLX with a $40 price target, a 116.86% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Guggenheim rated Amylyx Pharmaceuticals, Inc. ($AMLX) "buy" with a $40 price target on June 25, 2026.
Since the rating, $AMLX is up 4.8% after 1 week, up 11.8% after 1 month and up 51.0% to date (from the $17.44 close on Jun 25, 2026).
AMLX
Amylyx Pharmaceuticals, Inc.
Key Points
- Guggenheim reiterated its buy rating on AMLX, setting a $40 price target as of June 25, 2026.
- Guggenheim's $40 price target implies 116.86% upside from Amylyx Pharmaceuticals, Inc.'s ($AMLX) current $18.45 share price.
- AMLX shares traded near $16.94 on Thursday, with notable insider buying activity reported in June.
- Institutional investors like FMR LLC and Janus Henderson Group adjusted their AMLX holdings recently.
Get $AMLX trade alerts by text
We text you when insiders, Congress or big funds trade $AMLX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amylyx Pharmaceuticals, Inc. alert may contain errors. Disclosures
Guggenheim has reiterated its buy rating on AMLX, setting a price target of $40. This update came on June 25, 2026, as analyst Seamus Fernandez continues to see potential in the stock.
Other Institutional Activity in AMLX
FMR LLC slightly increased its holdings in AMLX by 112,122 shares, bringing its total to 16,630,541 shares valued at approximately $231.16 million, marking a 0.7% increase. Meanwhile, BlackRock, Inc. reduced its stake by 225,595 shares, now holding 8,828,836 shares worth around $122.72 million, a 2.5% decrease. Janus Henderson Group PLC significantly boosted its position by 520,201 shares, resulting in a total of 4,986,073 shares valued at $69.26 million, reflecting an 11.6% increase.
Amylyx Pharmaceuticals, Inc. Stock Down 43.1%
Shares of AMLX traded near $16.94 on Thursday. The stock has seen various institutional movements, which may affect its future performance. Investors are keeping an eye on these changes as they could impact AMLX's market dynamics.
$AMLX price target
Amylyx Pharmaceuticals, Inc. daily closes and this analyst's $40 target. Not advice.
Insider Buying and Selling at Amylyx Pharmaceuticals, Inc.
Recent insider activity at AMLX includes several purchases. On June 4, 2026, insiders like George Milne Jr., Daphne Quimi, and Karen Firestone each acquired 24,372 shares. Additionally, on May 21, 2026, Karen Firestone purchased 3,800 shares at an average price of $13.51.
Analysts Set New Price Targets
On June 25, 2026, Guggenheim maintained its buy rating on AMLX with a $40 price target. Earlier, on April 28, 2026, Mizuho also maintained a buy rating, setting a target of $21. The consensus among analysts remains positive, with a general buy recommendation and a variety of price targets reflecting different levels of optimism.
Bottom Line
Guggenheim's reiterated buy rating and $40 price target show confidence in AMLX's potential. Investors will be watching institutional and insider activities for further signals. Remember, 13F filings and analyst ratings offer insights but are not current positions or advice.
Related Filing Alerts
Source: Guggenheim's rating change on $AMLX (Jun 25, 2026). Written by software, not financial advice. How we make alerts